Dabigatran backed for PBS listing again

The new anticoagulant dabigatran (Pradaxa) has yet again been recommended for a PBS listing for stroke prevention in atrial fibrillation, its manufacturer claims.

Official confirmation is not expected for another three weeks but Boehringer Ingelheim said it "understands that the Pharmaceutical Benefits Advisory Committee has recommended Pradaxa for a third time ... however no further comments can be made at this time".

Expert Insight: Anticoagulation